Skip to main content

Featured

Daily Markets Update: TSX Hits Six-Week Low, Dow Sheds 849 Points as Nvidia Beat Lifts Asia

  Canadian Money Brief  |  Daily Markets Update Wednesday, November 18, 2026  •  Covers Tuesday’s closes plus Wednesday’s Asia and early Europe Canada’s main stock index closed Tuesday at 35,315.30 , down 1.14% . It was the TSX’s fourth straight decline and its lowest close in nearly six weeks, as a tech-led selloff rolled around the globe ahead of Nvidia’s earnings. On Wall Street, the Dow lost 848.75 points and the S&P 500 fell for a fourth straight session to its lowest close since late July. Then came the reversal. After the closing bell, Nvidia reported results and a forecast that both topped expectations, its shares jumped in after-hours trading, and Asian markets rebounded on Wednesday. Whether that relief lasts is the question for today, with Fed meeting minutes due at 2:00 p.m. ET. Markets at a Glance Market Level Change Canada (Tuesday close) S&P/TSX Composite 35,315.30 −406.83 (−1.14%) Canadian dollar 69.97¢ US (C$1.4293) +0.03¢ vs. Monday Ca...

article

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Comments